The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight.
The maximum duration of this study is up to 61 weeks.
Have a confirmed diagnosis of Crohn's disease (CD) or perianal fistulizing CD
hypertension
Type 2 diabetes mellitus (T2DM)
dyslipidemia
Have a current diagnosis of Ulcerative Colitis (UC), inflammatory bowel disease-unclassified (formerly known as indeterminate colitis), or primary sclerosing cholangitis.
Have more than 2 missing segments of the following 5 segments: terminal ileum, ·right colon, transverse colon, ·left colon, and rectum.
Currently have or are suspected to have an abscess.
Have a stoma, ileoanal pouch, or ostomy.